The Administrative Core of the North American Mitochondrial Disease Consortium (NAMDC) will provide critical organizational and strategic support to assure the overall success of the Center in accordance with NIH Rare Disease Clinical Research Network (RDCRN) programmatic objectives. The Core will have a Principal Investigator, Administrative Director, and Statistical Director with ultimate responsibility for the Center's scientific, clinical research and training/educational operations. These individuals plus three other NAMDC investigators will form an Executive Committee that meets regularly to assess and evaluate the program and its operations. An External Advisory Committee composed of researchers, clinicians and patient advocates will advise the Center's leadership and Executive Committee.
The specific aims of the Core are 1) to provide broad-based administrative support to NAMDC, 2) work with the External Advisory Committee to assure that NAMDC operates to benefit the mitochondrial disease research and patient communities, 3) manage the internal and external communications of NAMDC, and 4) promote collaboration with investigators outside of NAMDC and assure sharing of resources. Other specific functions include fiscal management, administration of subcontract/consortium agreements, communication with NIH Program staff and the RDCRN Steering Committee, resolution of unlikely conflicts/conflicts of interest and facilitating interactions with patient advocacy groups including the United Mitochondrial Disease Foundation (UMDF). The Core will also maintain an internal website to manage internal documents and communications with NAMDC sites as well as an external website to publically communicate NAMDC's mission and the availability of training opportunities and core services.
To fulfill the mission of NAMDC to advance understanding and treatment of mitochondrial diseases, the NAMDC Administrative Core will have ultimate responsibility for the Center's scientific, clinical research and training/educational operations. A NAMDC Executive Committee and an External Advisory Committee will assess and evaluate the NAMDC programs and its operations.
|Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66|
|Shen, Lishuang; Diroma, Maria Angela; Gonzalez, Michael et al. (2016) MSeqDR: A Centralized Knowledge Repository and Bioinformatics Web Resource to Facilitate Genomic Investigations in Mitochondrial Disease. Hum Mutat 37:540-8|
|Engelstad, Kristin; Sklerov, Miriam; Kriger, Joshua et al. (2016) Attitudes toward prevention of mtDNA-related diseases through oocyte mitochondrial replacement therapy. Hum Reprod 31:1058-65|
|Karaa, Amel; Kriger, Joshua; Grier, Johnston et al. (2016) Mitochondrial disease patients' perception of dietary supplements' use. Mol Genet Metab 119:100-8|
|Marin, Samantha E; Saneto, Russell P (2016) Neuropsychiatric Features in Primary Mitochondrial Disease. Neurol Clin 34:247-94|
|Al-Mehmadi, Sameer; Splitt, Miranda; For DDD Study group* et al. (2016) FHF1 (FGF12) epileptic encephalopathy. Neurol Genet 2:e115|
|Huang, Xiaoping; Bedoyan, Jirair K; Demirbas, Didem et al. (2016) Succinyl-CoA synthetase (SUCLA2) deficiency in two siblings with impaired activity of other mitochondrial oxidative enzymes in skeletal muscle without mitochondrial DNA depletion. Mol Genet Metab :|
|Saneto, Russell P (2016) Alpers-Huttenlocher syndrome: the role of a multidisciplinary health care team. J Multidiscip Healthc 9:323-33|
|Torres-Torronteras, Javier; Cabrera-PÃ©rez, Raquel; Barba, Ignasi et al. (2016) Long-Term Restoration of Thymidine Phosphorylase Function and Nucleoside Homeostasis Using Hematopoietic Gene Therapy in a Murine Model of Mitochondrial Neurogastrointestinal Encephalomyopathy. Hum Gene Ther 27:656-67|
|ServiÃ¡n-Morilla, Emilia; Takeuchi, Hideyuki; Lee, Tom V et al. (2016) A POGLUT1 mutation causes a muscular dystrophy with reduced Notch signaling and satellite cell loss. EMBO Mol Med 8:1289-1309|
Showing the most recent 10 out of 38 publications